DEA Places Insomnia Drug Into Schedule IV
The Drug Enforcement Administration is placing the newly approved drug Quiviviq (daridorexant) in Schedule IV of the Controlled Substances Act, it said in an interim final rule. Effective April 7, daridorexant, which was granted FDA approval in January, is subject…
Sign up for a free preview to unlock the rest of this article
Communications Daily is required reading for senior executives at top telecom corporations, law firms, lobbying organizations, associations and government agencies (including the FCC). Join them today!
to new registration, labeling, record-keeping, and import and export requirements. DEA is accepting comments on the rule until May 9.